Aurobindo Pharma Ltd Analyst Rating
based on 28 analysts
71.43%
Buy
14.29%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma Ltd. An average target of ₹1537.14
Source: S&P Global Market Intelligence
Aurobindo Pharma Ltd Share analysis
Aurobindo Pharma Ltd price forecast by 28 analysts
Upside of21.04%
High
₹1930
Target
₹1537.14
Low
₹1225
Aurobindo Pharma Ltd target price ₹1537.14, a slight upside of 21.04% compared to current price of ₹1298.3. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:19.99%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:42.91%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Ltd Performance
Day's Low
Day's High
₹1,265.95Day's Price Range₹1,307.2552 Week's Low
52 Week's High
₹958.552-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | + 1.21 % |
| 3 Month Return | -13.06 % |
| 1 Year Return | + 17.57 % |
| Market Stats | |
| Previous Close | ₹1,269.95 |
| Open | ₹1,273.00 |
| Volume | 26.82L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹74,411.27Cr |
Aurobindo Pharma Ltd Key Statistics
| P/E Ratio | 20.74 |
| PEG Ratio | 0.96 |
| Market Cap | ₹74,411.27 Cr |
| P/B Ratio | 3.24 |
| EPS | 54.09 |
| Dividend Yield | 0.41 |
| Sector | Pharmaceuticals |
| ROE | 10.35 |
Aurobindo Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹74,411.27 Cr | 34.59% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹14,076.40 Cr | -2.78% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹97,846.19 Cr | 56.16% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹62,184.94 Cr | 24.35% | 0.53 | NA | NA | |
| BUY | ₹38,530.56 Cr | 8.22% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Aurobindo Pharma Ltd Mutual Fund Holdings
About Aurobindo Pharma Ltd
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Share Price: ₹1298.30 per share as on 30 Dec, 2024 04:01 PM
Market Capitalisation: ₹74,411.27Cr as of today
Revenue: ₹7,646.21Cr as on September 2024 (Q3 24)
Net Profit: ₹816.95Cr as on September 2024 (Q3 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Aurobindo Pharma Ltd
CuraTeQ Biologics Gains Approval for Cancer Biosimilar - 23 Dec, 2024
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received marketing authorization from the UK's MHRA for Bevqolva, a biosimilar of bevacizumab, enhancing treatment options for various cancers.Aurobindo Pharma's Diverse Customer Base Highlighted - 20 Dec, 2024
Aurobindo Pharma serves 443 customers across various sectors, including pharmaceuticals and chemicals, with 30 notable clients from the NSE 500 index as of June 30, 2024.Aurobindo Pharma Receives Significant Incentives - 19 Dec, 2024
Aurobindo Pharma is listed as one of the top five beneficiaries of government incentive schemes, receiving between Rs 150 crore and Rs 330 crore.Aurobindo Pharma Reports Strong Results Amid FDA Observations - 18 Dec, 2024
Aurobindo Pharma's Telangana unit received two procedural observations from the US FDA. Despite this, shares rose 2.89% following strong Q2 FY25 financial results, with net profit increasing by 8.6% YoY.Aurobindo Pharma Faces FDA Observations, Goldman Sachs Bullish - 17 Dec, 2024
Aurobindo Pharma's Apitoria unit received two procedural observations from the USFDA, causing a 2.53% drop in shares. Goldman Sachs remains optimistic, maintaining a buy rating with a target price of Rs 1,525.Aurobindo Pharma's Zefylti Gains EMA Approval - 16 Dec, 2024
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive EMA opinion for its filgrastim biosimilar Zefylti, boosting shares by 1.34%. The company is expanding its biosimilars portfolio in Europe.Aurobindo Pharma Faces Recall, Gains EMA Approval - 15 Dec, 2024
Aurobindo Pharma's subsidiary CuraTeQ Biologics received a positive opinion from the EMA for its biosimilar Zefylti. Meanwhile, Aurobindo Pharma USA is recalling over 100,000 bottles of Cinacalcet tablets due to GMP deviations.Aurobindo Pharma Faces GST Demand, Advances Biosimilar - 13 Dec, 2024
Aurobindo Pharma is facing a ₹11 crore GST demand for excess ITC claims while its subsidiary CuraTeQ Biologics received EMA's positive opinion for Zefylti biosimilar.Aurobindo Pharma Officials Under Investigation for Extortion - 06 Dec, 2024
Andhra Pradesh CID has issued a lookout notice against Aurobindo Pharma officials and a YSRCP MP for alleged extortion and coercion in a share acquisition case valued at Rs 3,600 crore. The investigation involves accusations of manipulating audits and threatening a businessman to sell shares at undervalued prices.Aurobindo Pharma Subsidiary Secures USFDA Approval - 05 Dec, 2024
Aurobindo Pharma's wholly-owned subsidiary, Eugia Pharma Specialities, has received USFDA approval to manufacture Pazopanib Tablets, a cancer treatment, with a market size of $106 million. The product is expected to launch in Q4 FY25.Aurobindo Pharma Addresses Market Concerns and Opportunities - 04 Dec, 2024
Aurobindo Pharma is highlighted by Investec for its product overlap with granules, while the company clarifies its non-involvement in Kakinada port operations amid controversy.Geojit Reaffirms Buy Rating for Aurobindo Pharma - 28 Nov, 2024
Geojit Financial Services maintains a BUY rating on Aurobindo Pharma with a target price of Rs 1,540, citing strong growth in key markets and a robust product pipeline. The company reported an 8% YoY revenue increase, driven by U.S. and European sales, and expects continued profitability with projected adjusted PAT growth of 12.6% YoY in FY25.Aurobindo Pharma Reports Strong Q2FY25 Performance - 27 Nov, 2024
Aurobindo Pharma's Q2FY25 consolidated revenue rose 8% YoY to Rs. 7,796 crore, driven by U.S. and European sales growth. EBITDA increased 11.6% YoY, with a revised target price of Rs. 1,540. The company maintains a BUY rating.Aurobindo Pharma Partners for Respiratory Product Development - 25 Nov, 2024
Aurobindo Pharma's US subsidiary has entered a $25 million collaboration with a global pharma major for developing respiratory products, sharing costs capped at $90 million. The partnership is expected to last 3-5 years, enhancing Aurobindo's market position.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPromoter Holding Up
Promoters have increased holdings from 51.80% to 51.82% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 9 quarters, 5.79K Cr → 7.93K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, AUROPHARMA stock has moved up by 1.4%
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 50.2% return, outperforming this stock by 32.6%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.1% return, outperforming this stock by 47.5%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 919.22 Cr → 817.38 Cr (in ₹), with an average decrease of 11.1% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.70% to 6.46% in Sep 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.73% to 16.59% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 19.17% to 18.53% in Sep 2024 quarter
News
H-1B Visa Changes Impacting Indian IT Firms' Cost Structures
Tata Consultancy Services (TCS), Infosys, and Wipro, which are among the largest recipients of H-1B visas, will also focus on enhancing remote work and automation to offset rising costs.31 Dec, 2024 03:30 AMAndhra Pradesh Investments Expected to Create Jobs and Boost Economy
Tata Consultancy Services (TCS) will invest ₹80 crore to expand its operations at Millennium Towers in Visakhapatnam, covering an area of 2,08,280 square feet, which will create 2,000 jobs.30 Dec, 2024 09:00 PMStocks to Buy for Long Term: TCS, Infosys, Reliance, HDFC Bank
Buying range: ₹ 3,600-3,550 | Target price: ₹ 4,400 | Stop loss: ₹ 3,200 The stock appears to be forming a head and shoulders pattern at the current juncture, though the neckline is yet to be breached. Declining volumes at the top suggest a loss of momentum, while the weekly RSI exhibits bearish divergence, signalling potential weakness. Additionally, TCS has recently completed its 5-wave Elliott Wave structure, with waves A and B already in place. The pending C wave is projected to target the ₹3,600 level, which aligns with a 50 per cent retracement of the entire 5-wave structure. This creates a potential accumulation zone between ₹3,600-3,550 for long-term investors, with an upside target of ₹4,400. To manage risk, a stop loss below ₹3,200 on a daily closing basis is recommended, said Patel.30 Dec, 2024 12:15 PMAurobindo Pharma Ltd Financials
Index Inclusions
Aurobindo Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.03 | |
| Foreign Institutions | 16.59% | ||
| Mutual Funds | 18.53% | ||
| Retail Investors | 6.46% | ||
| Others | 6.61% | 17.96 |
Aurobindo Pharma Ltd Key Indicators
Aurobindo Pharma Ltd Valuation
Aurobindo Pharma Ltd in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (20.74x)
December 27, 2024
Industry (56.94x)
December 27, 2024
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Ltd Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit jumped 7.95% since last year same period to ₹817.38Cr in the Q2 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated -11.08% fall in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.35%.
Read More about Dividends
Aurobindo Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Aurobindo Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Aurobindo Pharma Ltd shares.
Aurobindo Pharma Ltd (AUROPHARMA) share price today is ₹1298.3
Aurobindo Pharma Ltd is listed on NSE
Aurobindo Pharma Ltd is listed on BSE
- Today’s highest price of Aurobindo Pharma Ltd is ₹1307.25.
- Today’s lowest price of Aurobindo Pharma Ltd is ₹1265.95.
PE Ratio of Aurobindo Pharma Ltd is 20.74
PE ratio = Aurobindo Pharma Ltd Market price per share / Aurobindo Pharma Ltd Earnings per share
Today’s traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 26.82L.
Today’s market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹74411.27Cr.
| Aurobindo Pharma Ltd(AUROPHARMA | Price |
|---|---|
52 Week High | ₹1592 |
52 Week Low | ₹958.5 |
Aurobindo Pharma Ltd(AUROPHARMA) share price is ₹1298.3. It is down -18.45% from its 52 Week High price of ₹1592
Aurobindo Pharma Ltd(AUROPHARMA) share price is ₹1298.3. It is up 35.45% from its 52 Week Low price of ₹958.5
| Aurobindo Pharma Ltd(AUROPHARMA | Returns |
|---|---|
1 Day Returns | 28.35% |
1 Month Returns | 1.21% |
3 Month Returns | -13.06% |
1 Year Returns | 17.57% |